Comera Life Sciences Holdings, Inc.

CMRA

US20037C1080

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 01:20:57 2024-05-13 pm EDT			5-day change	1st Jan Change
0.0212 ^USD	0.00%		0.00%	-61.45%

Jan. 30	Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes	CI
Jan. 30	Comera Life Sciences Holdings, Inc. Announces Changes to Its Board	CI

Comera Life Sciences Holdings, Inc. announced that it has received $3.561238 million in funding

January 03, 2023

On January 4, 2023, Comera Life Sciences Holdings, Inc. closed the transaction.

Latest news about Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes	Jan. 30	CI
Comera Life Sciences Holdings, Inc. Announces Changes to Its Board	Jan. 30	CI
Comera Life Sciences Holdings, Inc. announced that it has received $1.5 million in funding	Dec. 28	CI
Comera Life Sciences Holdings, Inc.(OTCPK:CMRA) dropped from S&P TMI Index	Nov. 21	CI
Comera Life Sciences Holdings, Inc.(OTCPK:CMRA) dropped from NASDAQ Composite Index	Nov. 16	CI
Comera Life Sciences Holdings, Inc. Appoints Dorothy Clarke to Board of Directors	Nov. 13	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q3 Revenue $136,310	Nov. 09	MT
Comera Life Sciences Holdings, Inc. Announces Resignation of Neal Muni, MD as Executive Vice President and Chief Operating Officer	23-10-06	CI
Comera Life Sciences Holdings, Inc. announced that it has received $4.069993 million in funding	23-09-10	CI
Comera Life Sciences Holdings, Inc. Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities	23-08-16	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q2 Revenue $315.1M	23-08-10	MT
Comera Life Sciences Holdings, Inc. Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore(TM) Platform	23-08-08	CI
Comera Life Sciences Holdings, Inc. announced that it expects to receive $4.069993 million in funding	23-07-30	CI
Comera Life Sciences Holdings, Inc. Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients	23-07-20	CI
Comera Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Reports Q1 Revenue $392.9M	23-05-11	MT
Comera Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-03-16	CI
Earnings Flash (CMRA) COMERA LIFE SCIENCES Posts Q4 Revenue $156,120	23-03-16	MT
North American Morning Briefing : Payrolls Shocker, China Spat to Weigh on Stocks	23-02-06	DJ
Insider Buy: Comera Life Sciences Holdings	23-01-06	MT
Insider Buy: Comera Life Sciences Holdings	23-01-06	MT
Comera Life Sciences Holdings, Inc. Announces Board Resignations	23-01-04	CI
Comera Life Sciences Holdings, Inc. announced that it has received $3.561238 million in funding	23-01-03	CI

Chart Comera Life Sciences Holdings, Inc.

Duration

Period

Chart Comera Life Sciences Holdings, Inc.

More charts

Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The Company is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohnâs and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partnersâ biologic medicines to deliver enhanced SQ formulations.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COMERA LIFE SCIENCES HOLDINGS, INC.	-61.45%	652K
MODERNA, INC.	+29.73%	48.16B
IQVIA HOLDINGS INC.	-1.27%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+10.16%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-23.07%	18.96B
BIO-TECHNE CORPORATION	+8.38%	12.92B
MEDPACE HOLDINGS, INC.	+28.92%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.07%	11.77B

Other Biotechnology & Medical Research